Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer (TIME 2 CHANGE)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: April 17, 2009
Last updated: April 19, 2010
Last verified: April 2010
There are different types of hormonal therapy medicines for the treatment of hormone-receptor-positive breast cancer. The purpose of this study is to determine the evolution of two types of hormonal treatment (the drug called "tamoxifen" and a group of medicines called "aromatase inhibitors") during two time periods of 12 months each, in years 2006 and 2008, in the northeast Italian regions. The study will include post-menopausal women who have initiated hormonal therapy medicines in 2006. The study will also verify the rate of implementation of the updated national and international recommendations for the use of adjuvant hormonal therapy in the hormone-receptor-positive breast cancer.

Post Menopausal
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Retrospective Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer in Two Successive Time Periods

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Relative frequencies of the first adjuvant hormonal treatment (tamoxifen vs aromatase inhibitor) started during two time periods of 12 months each - the years 2006 and 2008 [ Time Frame: May-July 2009 ]

Secondary Outcome Measures:
  • Relative frequencies of the type of initial treatment: upfront (a single drug - tamoxifen or aromatase inhibitor) or early switch (planned sequence of tamoxifen and inhibitor) [ Time Frame: May-July 2009 ]
  • Type of treatment and relative percentages of treatment undertaken by the patients after interruption of the first hormonal therapy [ Time Frame: May - July 2009 ]

Enrollment: 515
Study Start Date: July 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Post-menopausal patients with breast cancer already treated with advjuvant hormonal therapy.

Inclusion Criteria:

  • Post-menopausal patients with surgically treated breast cancer who started adjuvant hormonal therapy between January 2006 and December 2006 or between January 2008 and December 2008
  • Documented evidence of the way adjuvant hormonal treatment was initiated.

Exclusion Criteria:

  • Pre- or peri-menopausal patients with surgically treated breast cancer who started adjuvant hormonal therapy
  • Patients already enrolled in clinical studies aimed at investigating hormone therapies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00884143

Research Site
Aviano, PN, Italy
Research Site
Trento, Italy
Research Site
Verona, Italy
Sponsors and Collaborators
Study Chair: Davide Meani, Dr. AstraZeneca S. p. A.
Study Director: Raffaele Sabia AstraZeneca S.p.A
  More Information

Responsible Party: Raffaele Sabia MC MD, AstraZeneca Identifier: NCT00884143     History of Changes
Other Study ID Numbers: NIS-OIT-ARI-2008/1
Study First Received: April 17, 2009
Last Updated: April 19, 2010

Keywords provided by AstraZeneca:
adjuvant hormonal therapies
breast cancer
Adjuvant hormonal therapy in patients post menopausal with breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 22, 2017